{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:05:13Z","timestamp":1785528313777,"version":"3.56.0"},"reference-count":14,"publisher":"Informa UK Limited","issue":"14","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2023,12,6]]},"DOI":"10.1080\/10428194.2023.2254876","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T04:48:36Z","timestamp":1696567716000},"page":"2296-2305","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Combined analysis of the impact of second-generation BTK inhibitors on patient outcomes"],"prefix":"10.1080","volume":"64","author":[{"given":"Robert A.","family":"Redd","sequence":"first","affiliation":[{"name":"Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josie","family":"Ford","sequence":"additional","affiliation":[{"name":"Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5348-6065","authenticated-orcid":false,"given":"Matthew","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-9257","authenticated-orcid":false,"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[{"name":"Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3062-6819","authenticated-orcid":false,"given":"Jacob D.","family":"Soumerai","sequence":"additional","affiliation":[{"name":"Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014960"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001160"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_3_3_8_1","first-page":"2021","volume-title":"EHA Congress","author":"Hillmen P","year":"2021","unstructured":"Hillmen P, Eichhorst B, Brown JR, et\u00a0al. First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma. EHA Congress; 2021: HemaSphere; 2021."},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.32614\/RJ-2011-004"},{"key":"e_1_3_3_11_1","unstructured":"R RRFGR. Kmdata: a database of reconstructed individual patient level data from oncology clinical trials. R Package Version 1.0.1. 2022. https:\/\/github.com\/raredd\/kmdata"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"e_1_3_3_13_1","volume-title":"R: a language and environment for statistical computing","author":"Team RC","year":"2022","unstructured":"Team RC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2022."},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-109973"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1978288"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2023.2254876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T15:07:18Z","timestamp":1727276838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2023.2254876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":14,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,12,6]]}},"alternative-id":["10.1080\/10428194.2023.2254876"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2023.2254876","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}